You just read:

Eisai Submits Supplemental Application to FDA for Use of its Antiepileptic Drug FYCOMPA® (perampanel) as Monotherapy for the Treatment of Partial Onset Seizures

News provided by

Eisai Inc.

26 Sep, 2016, 13:30 ET